RP Cure Tracker

Trials / NCT00874783

Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases

Recruiting now Observational Natural history / observational

Sponsor
Hadassah Medical Organization
Treatment
Not listed
Gene
Not stated
Conditions
Neurodegenerative Disorders
Ages
18 Years to no upper limit
Enrollment
120 participants
Started
2009-04
Main results expected
2030-12
Results posted
Not yet
Record last updated
2025-03-04

What the study is testing

Human fibroblasts and possibly other human somatic cells may be reprogrammed into induced pluripotent stem (iPS) cells by the forced expression of transcription factors (1-5). The iPS cells seem to share many properties with human embryonic stem cells.

Induced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation.

The major goal of the project is to develop human iPS cells from cell cultures from skin biopsies or the patient's hair. The iPS cells will be developed primarily for modeling diseases and drug discovery as well as basic research, and for developing the technology that may eventually allow the use of iPS cells for future transplantation therapy. The iPS cells developed in the course of this application are not intended for use in transplantation therapy. Future development of iPS cells for clinical transplantation therapies will be subjected to the appropriate authorization by ethical and regulatory committees.

Where it runs

Israel (1)

Open on ClinicalTrials.gov for contacts and eligibility